在前列腺癌中接受雄激素缺乏治疗后的二次癌症:全国性研究
Jae Heon Kim1, Gi Hwan Bae2, Jaehun Jung2,3
1Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
The world journal of men's health
|April 12, 2024
概括
在前列腺癌患者中使用雄激素剥夺疗法 (ADT) 与患二次癌症的风险增加有关,特别是大脑和中枢神经系统 (CNS) 癌症. 然而,ADT也显示了对其他几种癌症的风险降低.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 癌症流行病学 癌症流行病学
背景情况:
- 雄激素信号传递在各种癌症中发挥作用,使雄激素剥夺疗法 (ADT) 成为潜在的治疗策略.
- 了解ADT与二次癌症之间的关联对于患者管理至关重要.
研究的目的:
- 调查雄激素剥夺疗法 (ADT) 与二次癌症发病率之间的关联,不包括前列腺癌.
- 在一大群为前列腺癌治疗的男性中分析癌症特异性发病率.
主要方法:
- 一项全国性基于人口的队列研究包括170,416名在2002年至2017年期间被诊断患有前列腺癌的男性.
- 使用倾向分数匹配 (PSM) 来创建可比的ADT和非ADT组.
- 考克斯的比例危险回归模型分析了二次癌症的风险.
主要成果:
- 与非ADT组相比,ADT组的二次癌症发病率总体风险较高 (调整HR为1.344).
- 在ADT组中观察到大脑和中枢神经系统 (CNS) 癌症的风险显著增加 (调整HR:1.648).
- 在ADT组显示胃,结肠/直肠,肝/IBD,胆囊,肺,膀和癌的风险降低.
结论:
- 雌激素剥夺疗法 (ADT) 影响各种二次癌症的发生率.
- 这些发现突出了ADT和二次癌症风险之间的复杂关系,在不同类型的癌症中观察到增加和减少的风险.
相关概念视频
Disorders of the Male Reproductive System
402
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
402
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


